Ignite Creation Date:
2025-12-26 @ 10:44 PM
Ignite Modification Date:
2026-01-11 @ 3:14 PM
Study NCT ID:
NCT03217812
Status:
COMPLETED
Last Update Posted:
2024-04-25
First Post:
2017-07-13
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)
Sponsor:
Janssen Research & Development, LLC
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2017-11-23
Start Date Type:
ACTUAL
Primary Completion Date:
2020-07-02
Primary Completion Date Type:
ACTUAL
Completion Date:
2024-03-08
Completion Date Type:
ACTUAL
First Submit Date:
2017-07-13
First Submit QC Date:
None
Study First Post Date:
2017-07-14
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-04-24
Last Update Post Date:
2024-04-25
Last Update Post Date Type:
ACTUAL